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Background
There is increasing evidence supporting the hypothesis of
a beneficial effect of highly active antiretroviral therapy
(HAART) on the evolution and outcome of chronic liver
disease (CLD) caused by hepatitis C virus (HCV) in HIV
co-infected patients. The relative merit of different drugs
or drug classes is, however, less well studied.
Methods
We performed a cross-sectional study on the VACH
Cohort, a multicenter cohort of HIV-infected individuals
in Spain, to ascertain the possible associations between
exposure to protease inhibitors (PI) or to non-nucleoside
analogues (NAN), and the outcome of HCV CLD. We
selected HCV co-infected patients who had ever initiated
HAART and who had at least one follow-up visit [treat-
ment evaluable (TE)]. We defined our main "exposure"
variable as the total time of treatment with any of, either,
PI's or NAN's. We evaluated "outcome" as the occurrence
of end stage CLD (ESLD), defined as any of: ascites,
oesophageal varices, hepatic encephalopathy, hepatore-
nal syndrome, portal hypertension, hepatocellular carci-
noma, or related diagnoses (i.e. upper gastrointestinal
bleeding, spontaneous bacterial peritonitis).
Summary of results
Out of 15,183 patients in the VACH database, 6,004 were
TE, of whom 2,669 (44,4%) were HCV co-infected; 128
patients (4.4%) developed an ESLD. Table 1 shows some
important features of this sub-cohort, according to study
group. The following factors (marked with * in Table 1)
were associated with ESLD in the univariate analyses:
being HBsAg-positive, nadir of CD4+ cell count, age and
prior diagnosis of AIDS. Exposure to either PI's or NAN's
was not. In a regression model, only HBsAg, age and nadir
CD4+ cell count remained associated with ESLD. In a sen-
sitivity analysis, Kaplan-Meier curves of time from initia-
tion of HAART to diagnosis of ESLD, restricted to patients
only exposed to one class of drugs, showed no differences
between PI's and NAN's.
Conclusion
In conclusion, we found no evidence to support the
hypothesis of a different effect of PI's and NAN's on the
occurrence of ESLD among HIV and HCV co-infected
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individuals. Hepatitis B co-infection, more profound
immunosupression and older age were associated with
this outcome.
Table 1: 
female prior AIDS* ever IVDU HBsAg+* mean age* 1st CD4 cell count log10 last viral load nadir CD4 count*
ESLD 17.4% 43.7% 84.1% 12.5% 36.7 303.3 2.50 128.7
Other 20.2% 34.2% 82.2% 5.3% 34.6 311.1 2.45 170.6Page 2 of 2
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